Aphria supports majority of Task Force recommendations
December 14, 2016
Aphria will be ready to participate in recreational market
Leamington, Ontario – December 14, 2016 – Aphria Inc. (“Aphria” or the “Company”) (TSX-V: APH or USOTCQB: APHQF) responds to the federal task force recommendations.
“Regulating a brand new industry is a complex undertaking that requires a great degree of thought and consideration. The Task Force’s mandate to provide recommendations that balance both the health and well-being of Canadians and the need to shut down the black market was no easy feat and we commend them on their thoughtful and thorough approach.” said Vic Neufeld, Chief Executive Officer of Aphria Inc.
Aphria supports the federal task force recommendation to keep two distinct systems in place for medical and recreational use and looks forward to clarity on the subject of taxation within the medical regime. “The needs of Canadian patients requiring access to cannabis for medical purposes are much different than those consuming recreational marijuana.” said Vic Neufeld. Aphria further supports the recommendation to allow distinct retail locations to support and service point of sale needs for recreational cannabis consumers.
The company is eager to review the government’s final regulations on promotion, advertising and marketing as well as packaging, as these consumer engagement requirements will be very important to the success of a regulated recreational market. The company believes transparent and regulated packaging and consumer communication have clear benefits in minimizing public health risks, combating the black market, and educating recreational marijuana users.
The recreational market represents a big opportunity for Aphria and the company has been actively planning its strategy for some time. “We look forward to the opportunity to participate in this new segment, and when the time comes, we will be ready to meet both medical and recreational needs for Canadians.”
We have a Good Thing Growing
Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders. We are the first public licensed producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters. For more information, visit aphriainc.com.
For further information please contact:
Mr. Vic Neufeld
Chief Executive Officer
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”,“believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements with respect to internal expectations, estimated margins, timing for completion of final TSX approval, expectations for future growing capacity and costs, the completion of any capital project or expansions, any commentary related to the legalization of marijuana and the timing related thereto, expectations of Health Canada approvals and expectations with respect to future production costs. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability of Aphria to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange (the “Exchange”) nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.